3-Ethyl-2-thiabicyclo<0.3.3>octadien-(3,5(1)) | 120267-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 3-Ethyl-2-thiabicyclo<0.3.3>octadien-(3,5(1))
• 英文别名: 2-ethyl-5,6-dihydro-4H-cyclopenta[b]thiophene；2-ethyl-5,6-dihydro-4H-cyclopenta[b]thiophene
• CAS: 120267-22-3
• 化学式: C₉H₁₂S
• 分子量: 152.26
• InChiKey: AIQRWJUPSAKGGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009062289A1

  公开（公告）日：2009-05-22

  Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

  公式I的化合物：其中c、R2、R3、R4、R5、R6、R7和R8按本说明定义，可用作HIV复制的抑制剂。
• CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：BLOMGREN Peter A.

  公开号：US20090082330A1

  公开（公告）日：2009-03-26

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  公式I的化合物能够抑制Btk，本文中对此进行了描述。描述了包含至少一个公式I化合物的药物组合物，以及至少一个从载体、佐剂和辅料中选择的药用辅料。描述了治疗患有对Btk活性抑制和/或B细胞活性有反应的某些疾病患者的方法。还描述了用于确定样本中存在Btk的方法。
• [EN] PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN INHIBITEUR DE L'INTÉGRASE DU VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2012138670A1

  公开（公告）日：2012-10-11

  The present invention is directed to an improved process for the preparation of Compounds of Formula (I) or salts thereof which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)- 2-methylquinolin-3-yl)acetic acid or salt thereof which is useful in the treatment of HIV infection. R4 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n) and (o); and R6 and R7 are each independently selected from H, halo and (C1-6) alkyl.

  本发明涉及一种改进的工艺，用于制备化合物的化合物（I）或其盐，该化合物在治疗HIV感染中有用。具体而言，本发明涉及一种改进的工艺，用于制备对治疗HIV感染有用的(2S)-2-叔丁氧基-2-(4-(2,3-二氢吡喃并[4,3,2-de]喹啉-7-基)-2-甲基喹啉-3-基)乙酸或其盐。其中R4从(a)、(b)、(c)、(d)、(e)、(f)、(g)、(h)、(i)、(j)、(k)、(l)、(m)、(n)和(o)组成的群中选择；R6和R7分别独立选择自H、卤素和（C1-6）烷基。
• PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：Barbosa JR. Antonio J.M.

  公开号：US20110301145A1

  公开（公告）日：2011-12-08

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了化学式I的化合物，其能够抑制Btk。本文还描述了包含至少一种化学式I化合物的制药组合物，以及至少选择自载体、佐剂和赋形剂中的一种药学可接受载体的制药组合物。本文还描述了治疗对Btk活性和/或B细胞活性抑制有响应的某些疾病的患者的方法。本文还描述了检测样品中Btk存在的方法。
• INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2220076B1

  公开（公告）日：2012-01-18